Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CalciMedica Inc CALC

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora... see more

Recent & Breaking News (NDAQ:CALC)

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

PR Newswire March 13, 2024

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

PR Newswire February 28, 2024

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora(TM) for the Treatment of Severe Acute Kidney Injury

PR Newswire February 13, 2024

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

PR Newswire February 7, 2024

CalciMedica Announces Private Placement of up to Approximately $55 Million

PR Newswire January 22, 2024

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

PR Newswire November 9, 2023

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

PR Newswire November 2, 2023

CalciMedica Announces Upcoming Presentations and Events in September

PR Newswire September 6, 2023

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

PR Newswire August 31, 2023

CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

GlobeNewswire August 10, 2023

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora(TM) in Acute Pancreatitis (AP)

GlobeNewswire August 9, 2023

CalciMedica Announces Relisting on Nasdaq

GlobeNewswire June 12, 2023

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

GlobeNewswire June 6, 2023

CalciMedica Expands Executive Team with New Appointments

GlobeNewswire May 23, 2023

CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

GlobeNewswire May 15, 2023

Graybug Announces Name and Trading Symbol Change

GlobeNewswire March 20, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLI, FMIA, GRAY

PR Newswire February 15, 2023

GRAYBUG VISION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graybug Vision, Inc. - GRAY

Business Wire February 14, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, IMGO, GRAY, USER

PR Newswire December 13, 2022

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - VVNT, SAL, GRAY, APEN

PR Newswire December 9, 2022